Business
Eli Lilly Supply Agreement
MedPal AI plc has secured approval for its subsidiary, MedPal Limited, to become an authorised purchaser of Eli Lilly pharmaceutical products in the UK, including Mounjaro, the leading GLP-1 medication for type 2 diabetes and weight management. This direct supply access is significant given Mounjaro's 79% market share in the UK GLP-1 sector and the substantial private prescribing market, which is projected to grow from £340 million in 2025 to £2 billion by 2033. The company's automated distribution centre in Swaffham, Norfolk, is equipped to handle increased demand, supporting MedPal AI's strategy to be a leading digital platform for weight management services. Disclaimer*
About this update from Medpal Ai Plc
[{"type":"text","content":"\n\n28 January 2026\nMedPal AI plc\n(\"MedPal AI\" or the \"Company\")\nEli Lilly Supply Agreement\nMedPal AI plc (AIM: MPAL), the AI-powered digital health company, is pleased to announce that MedPal Limited, its wholly owned subsidiary, has been approved as an authorised purchaser of Eli Lilly pharmaceutical products in the United Kingdom.\nThe approval enables the Company to purchase and dispense Eli Lilly's portfolio of medications, including Mounjaro® (tirzepatide), the GLP-1 receptor agonist approved for the treatment of type 2 diabetes and weight management.\nMarket Opportunity\nMounjaro is the UK's leading weight loss medication, commanding approximately 79% of the UK GLP-1 market and research indicates that approximately ten times more people in the UK purchase Mounjaro privately than receive it through the NHS, highlighting the substantial commercial opportunity in the private prescribing market. Alternative GLP-1 receptor Wegovy, which Medpal.clinic already supplies, represents 20% of the market. This approval means that it will now be able to offer GLP-1 patients their preferred medication.\nThe UK prescription weight loss medications market is forecast to grow from approximately £340 million in 2025 to £2 billion by 2033, driven by rising obesity prevalence and increasing adoption of GLP-1 therapies. An estimated 3.4 million people in the UK are eligible for tirzepatide treatment, with approximately 64% of adults in England classified as overweight or obese. Globally, the GLP-1 weight loss drugs market is projected to reach £120 billion by 2035. Direct supply access positions MedPal AI to serve the significant and growing private market demand through MedPal.clinic, where patients can access clinically supervised weight management pathways combining AI-powered triage with prescriber consultation.\nOperational Capability\nMedications will be dispensed from the Company's distribution centre in Swaffham, Norfolk, which utilises state-of-the-art robotic dispensing technology to ensure accuracy, efficiency and rapid fulfilment of patient orders. This automated infrastructure provides the scalability required to meet anticipated demand growth.\nThis development supports the Company's strategy to position MedPal.clinic as a leading digital platform for clinically supervised weight management services, combining AI-powered ...